The current project advances the manufacturing readiness of Allarta’s Microgel Technology using scale-up engineering methodologies. Additionally, Allarta is extending the market penetration potential...
Allarta Life Science Inc.
9 enregistrements totalisant 1,051,353.50 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $1,051,354 | 9 enregistrements |
Enregistrements
Non-cell permeating microgels are developed to promote cryopreservation with limited or no use of DMSO. This project aims to develop degradable microgels that are easy to separate from cell suspension...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Cell-based therapies for chronic disorders such as Type 1 Diabetes hold the promise of curative treatments. This project aims to developing robust yet immune-evasive hydrogel capsules to enable islet...
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The Project will support development of intellectual property capacity within the Firm.
To help identify gaps in Allarta's existing intellectual property portfolio
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Rese...